Nurix (NRIX) names Roy Baynes chair of Clinical & Commercialization

Nurix Therapeutics reported a board committee leadership change following the resignation of Dr. Kunkel.

Rhea-AI Filing Summary

Nurix Therapeutics reported a board committee leadership change following the resignation of Dr. Kunkel. The board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., who is already a board member and a member of the Clinical and Commercialization Committee, to serve as chair of that committee effective September 1, 2025. The change is administrative and focused on committee leadership; no financial data, transactions, or other operational actions are disclosed in the filing.

Positive

• Leadership continuity maintained by appointing an existing board member as committee chair
• Qualified replacement named with medical and academic degrees (MB.Bch., M.Med., Ph.D.)

Negative

• Resignation of a committee chair (Dr. Kunkel) creates governance turnover
• No further details provided on reasons for resignation or changes to committee priorities

Insights

Corporate Governance Analyst

TL;DR: Committee chair change preserves internal leadership continuity after a resignation.

The board replaced a departing committee chair by elevating an existing member, Roy D. Baynes, MB.Bch., M.Med., Ph.D., to chair the Clinical and Commercialization Committee effective September 1, 2025. This is a governance-level adjustment that keeps responsibility within the current board membership.

The main dependencies are the committee's ongoing agenda and whether the new chair alters priorities, but the filing contains no operational or financial details. Near-term investor impact is limited; monitor subsequent disclosures for committee charters, clinical or commercialization updates, or further leadership changes within one to three quarters.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did Nurix Therapeutics (NRIX) report in this 8-K?

The company reported the resignation of Dr. Kunkel and the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D. as chair of the Clinical and Commercialization Committee effective September 1, 2025.

Who is Roy D. Baynes and what role will he take at NRIX?

Roy D. Baynes is a current board member and member of the Clinical and Commercialization Committee who will serve as chair of that committee starting September 1, 2025.

Does the filing disclose any financial impact from the leadership change?

No. The filing contains no financial data, transactions, or operational measures tied to the leadership change.

Was a reason for Dr. Kunkel's resignation provided?

No. The filing simply notes the resignation and the committee chair appointment without explaining the reason.

When does the committee leadership change become effective?

The appointment of Roy D. Baynes as chair is effective September 1, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/22/2025 - 04:01 PM Learn about SEC filing dates

0001549595false00015495952025-08-192025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 19, 2025

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1700 Owens Street, Suite 205 San Francisco, California						94158
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers..

(b)

On August 19, 2025, Lori A. Kunkel, M.D., advised the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that she would resign as a Class III director of the Board, and as chair of the Clinical and Commercialization Committee of the Board (the "Clinical and Commercialization Committee"), and as a member of the Clinical and Commercialization Committee and the Compensation Committee of the Board, effective September 1, 2025. Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

In connection with Dr. Kunkel's resignation, the Board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., a member of the Board and the Clinical and Commercialization Committee, to serve as chair of the Clinical and Commercialization Committee, effective as of September 1, 2025.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: August 22, 2025			By:			/s/ Christine Ring
						Christine Ring, Ph.D., J.D.
						Chief Legal Officer

3